A New Treatment Option Offering Hope for People Living with Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

For people living with advanced cutaneous squamous cell carcinoma (CSCC),

treatment choices can sometimes feel limited, especially when surgery or radiation is no

longer an option. A recent announcement from Sun Pharmaceutical Industries Ltd.

brings encouraging news for patients and families facing this diagnosis.

Unloxcyt™ (cosibelimab-ipdl) is a newly available treatment for adults with metastatic

CSCC (cancer that has spread) or locally advanced CSCC that cannot be treated with

surgery or radiation. This therapy offers a new option for people who may have

previously had few alternatives, and it has shown promising results in helping control

the disease over time.

Unloxcyt is a type of immunotherapy called a checkpoint inhibitor, which works by

helping the body’s immune system to recognize and fight cancer cells. In clinical

studies, many patients experienced meaningful disease control, with responses that

lasted—an important outcome for those managing a long-term condition.

Dr. Ann W. Silk, a medical oncologist at Dana-Farber Cancer Institute and Assistant

Professor of Medicine at Harvard Medical School, highlights why this treatment matters:

“Patients with unresectable or metastatic CSCC now have a new and important

treatment option to manage their disease. Because these patients are often older and

may have other health conditions, it’s especially important to have a therapy that is both

effective and well tolerated.”

Dr. Silk is also a founding member of Skin Cancer Champions, a support platform

created to help patients and caregivers navigate their non-melanoma skin cancer

journey. Her perspective reflects the real-world needs of patients looking not just for

treatment, but for quality of life and support along the way.

In addition to the therapy itself, patients and caregivers can access help through the

Unloxcyt SUPPORT Program, which is designed to guide people throughout their

treatment experience. The program offers educational resources and assistance to help

patients feel informed and supported at every step. To learn more about Unloxcyt and

available support resources, patients and caregivers can visit http://www.unloxcyt.com or

speak with their healthcare team about whether this treatment may be right for them.

WHO WE ARE